Regeneron Pharmaceuticals, Inc. (REGN): analysis and signal as of September 7, 2026

Published on September 4, 2026 at 12:29 · Updated on September 11, 2026 at 12:18 · by Aurélien Ambert, QDNA

Exchange : NASDAQ · Sector : Healthcare

In short

The signal displayed on Regeneron Pharmaceuticals is moderate, with a vote of 3/3 and a score of -2,0. Second-quarter multi-driver growth and balance-sheet strength come up against a price above the average consensus target and a volatility regime deemed complacent.

Current signal: moderate (vote 3/3) divergence
Deterministic score: -2.0 → signal expected by the scale : no signal (September 10, 2026)
Layers: fundamentals : positive, price : positive, risks : neutral

Triggered rules

Rule	Weight
penalizes a PEG above 2, the anticipated growth is overpaid (overvalued fast grower)	-1.5
penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE	-1.0
moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger	+0.5

Thesis

Regeneron combines multi-driver growth, with revenue up 17 % in the second quarter, a 52 % increase for Eylea HD in the United States and 38 % growth for Dupixent, with a solid balance sheet evidenced by an M-Score of -2,54 with no Beneish alert and by a 1,2 Md$ share repurchase over the quarter. The stock however trades at 827,72 USD, above the average target put forward by the consensus, which limits the twelve-month upside. The Cboe risk regime also shows signs of complacency, with little hedging and a put/call ratio of 0,76 below its average. This configuration exposes the stock to a technical correction should volatility rise again.

Bull case

Second-quarter revenue reaches 4,3 Md$, up 17 %. Eylea HD gains 52 % in the United States and Dupixent grows 38 %, while the company devotes 1,2 Md$ to repurchasing its own shares over the quarter. The balance sheet shows 41,73 Md$ in assets against 31,71 Md$ in shareholders' equity, and the M-Score of -2,54 triggers no Beneish alert. Finally, the macroeconomic expansion regime provides a favourable framework for healthcare, a sector with a defensive profile.

Bear case

The price of 827,72 USD exceeds the average consensus target, which implies negative twelve-month upside. Eylea in its original formulation declines 12 % in the United States under pressure from biosimilars. A class action was furthermore filed on 26 August 2026. The Cboe volatility regime shows markers of complacency, with a VIX9D/VIX3M slope of -32 % and a put/call ratio of 0,76 (z of -1,39). Finally, the margin gap between GAAP and non-GAAP accounts reaches 5 points.

Scenarios

No quantified scenario is provided in the verdict. The favourable trajectory assumes that growth in Eylea HD and Dupixent continues to offset the decline of the original Eylea, supported by the share repurchase. The unfavourable trajectory would stem from a rise in volatility on a stock stretched 15 % above its moving averages and trading above the consensus target.

Risks

The main perils lie in biosimilar pressure on the original Eylea, down 12 % in the United States, and in the class action filed on 26 August 2026. The 5-point gap between GAAP and non-GAAP margins raises questions about the quality of reported results. The complacency of the Cboe volatility regime, with a VIX9D/VIX3M slope of -32 % and a put/call ratio of 0,76 below its average, increases the stock's sensitivity to a volatility shock. Finally, the valuation premium versus the consensus reduces the margin for error.

Market positioning (short sellers)

Short interest / shares outstanding: 2.66 %
Days to cover: 3.85
Settlement date: 2026-08-31
Source: FINRA (disseminated on 2026-09-12)

Market information published by FINRA (consolidated short interest, all venues), no directional comment.

Signal history (last 12 months)

Date	Signal	New fact
September 7, 2026	moderate (3/3)	Informative analysis, it does not constitute personalised advice.
September 4, 2026	moderate (3/3)	First verdict issued on the stock. The deterministic signal from the weighted rules comes out neutral at +0,00. Three positive layers of analysis converge at medium confidence, but this alignment is not enough to change the signal on a stock already stretched 15 % above its moving averages. Informative analysis, with no advisory value.

Frequently asked questions

What is the signal displayed on Regeneron Pharmaceuticals?

The signal is moderate, with a vote of 3/3 and a score of -2,0. The three layers of analysis converge at medium confidence and the deterministic signal from the weighted rules comes out neutral at +0,00. This slightly negative score mainly reflects the stock's stretched valuation versus the consensus, not a weakness in operating fundamentals.

Why is the twelve-month upside deemed limited?

The price of 827,72 USD sits above the average consensus target, which corresponds to negative twelve-month upside according to analysts. The stock has moreover stretched 15 % above its moving averages. This double extension fuels the scenario of a technical correction should volatility rise again.

Which growth drivers emerge from the second quarter?

Second-quarter revenue amounts to 4,3 Md$, up 17 %. Eylea HD advances 52 % in the United States and Dupixent 38 %. The company allocated 1,2 Md$ to repurchasing its own shares over the quarter. The macroeconomic expansion regime offers a favourable framework for healthcare, a sector with a defensive profile.

What risks weigh on the stock?

A class action was filed on 26 August 2026. Eylea in its original formulation declines 12 % in the United States under pressure from biosimilars. The margin gap between GAAP and non-GAAP accounts reaches 5 points. The Cboe volatility regime shows signs of complacency, with a VIX9D/VIX3M slope of -32 % and a put/call ratio of 0,76.

What do the balance sheet and the M-Score reveal?

The balance sheet shows 41,73 Md$ in assets against 31,71 Md$ in shareholders' equity. The M-Score of -2,54 triggers no Beneish alert, which rules out an accounting manipulation signal. This financial strength provides support against competitive pressures on Eylea and ongoing litigation.

Sources

The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.

July 30, 2026 — 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits (SEC · 8-K)
July 30, 2026 — 10-Q (SEC · 10-Q)
July 6, 2026 — 2.02 Results of Operations and Financial Condition (SEC · 8-K)
June 17, 2026 — 5.07 Submission of Matters to a Vote of Security Holders (SEC · 8-K)
April 29, 2026 — 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits (SEC · 8-K)

Automated AI analysis: limitations and transparency

This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
Tool and analysis: QDNA, Aurélien Ambert.
Analysis (arbitration) completed on September 7, 2026; this page was completed on September 11, 2026 at 12:18 (UTC).
Interests: no position in the stock analysed (REGN) is recorded in the data consulted on September 12, 2026 (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
Methodology: analysis chain, score formula and scale described on the public methodology page.
Analysis horizon: 2035.